|会社名||Catalent Inc （CTLT キャタレント）|
|業種||医薬品 医療関連（Health Care）|
|概要||事業概要 キャタレント(Catalent Inc)は薬品、生物製剤及び顧客・動物健康製品向けの配達技術と開発ソリューションの提供を行う。同社は3つの事業区分により構成される。軟質ゲル技術事業は処方箋・顧客健康ソフト・カプセルまたは軟質ゲルの生産・開発・製造に従事する。薬物配達ソリューション事業は処方箋・顧客・動物健康製品の生産・開発・製造、ブロー・フィル・シール・ユニット・ドーズ製造、生物的細胞株開発、分析と生物分析開発及びテスト・サービスの提供に従事する。臨床供給サービス事業は診療試験薬物と生物製剤の製造・包装・ラベル付け・ストレージ・販売・在庫管理、FastChain臨床供給サービスの提供、臨床電子ソリューションと情報及びグローバルな対照薬供給サービスの提供に従事する。 キャタレントは米国の製薬会社。処方箋薬、市販薬、生物製剤向けに経口剤、注射剤、吸引剤などの発見、開発、受託製造を行う。また、治験薬の製造・供給、各種包装・容器の製造、在庫管理サ―ビスを提供。顧客は米国、欧州、アジア、南米の大手製薬会社や新興製薬企業。|
|代表者氏名||John R. Chiminski|
|代表者役職名||Chairman of the Board Chief Executive Officer|
|決算概要||決算概要 BRIEF: For the six months ended 31 December 2018 Catalent Inc revenues increased 2% to $1.17B. Net income before extraordinary items increased 24% to $34.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Debt refinancing costs decrease of 64% to $4.2M (expense) Foreign currency (gains) and losses decrease of 65% to $2.4M (expense).|
Global Contract Development & Manufacturing Organization Market (2020 to 2024) - Insights & Forecast with Potential Impact of COVID-19 - ResearchAndMarkets.com 2021/01/29 11:36:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Contract Development & Manufacturing Organization (CDMO) Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2024)" report has been added to ResearchAndMarkets.com's offering. The global CDMO market is estimated to reach US$241.3 billion in 2024, growing at a CAGR of 9.80% for the period spanning from 2020 to 2024. Companies Mentioned Biomerieux SA Catalent, Inc. Evotec SE Lonza Group AG Recipharm AB Thermo Fisher Scientific Inc. The
Biotherapeutics Cell Line Development Market with Pandemic Analysis, Growth Rate, New Trend Analysis Forecast To 2027 | Becton Dickinson and Company, Beckman Coulter, Boehringer Ingelheim Group, Catalent 2021/01/20 17:12:18 OpenPR
Biotherapeutic drug products encompass various active substances. These substances are either produced or extracted from biological sources. These biotherapeutic drug therapy products are obtained from various recombinant DNA technologies such as interleukins, interferons, etc. There are various advantages of these
Clinical Trial Supply and logistics Market Reach at High CAGR with Technology Innovative, and advanced of applications Major key Companies: DHL, Movianto, Catalent, Patheon, Marken, FedEx, Almac Group 2021/01/18 18:04:15 OpenPR
Clinical trials are research studies performed in a group of people called sample that are aimed at evaluating a medical, surgical, or behavioral intervention. It is a primary way for researchers to measure safety, efficacy, side effects and positive effects
Acorda Stock at $35 a Share? This Analyst Thinks It’s Possible 2021/01/16 01:19:58 Yahoo Finance
It's been a stellar week for Acorda Therapeutics (ACOR) investors. The stock skyrocketed over 60% after the company announced it is selling its manufacturing operations for Inbrija - Acorda’s FDA approved treatment of OFF episodes in Parkinson's disease - which should also reduce its headcount by 16%. The company’s 90,000 square-foot, FDA-inspected CGMP facility in Chelsea, Massachusetts, is being sold off to Catalent, along with the facility’s employees. The net proceeds from the deal will pocket the company approximately $70 million in cash and will reduce its annual operation costs by $40 million. Along with a recent at-the-market offering, the sale provides enough cash for the coffers to swing the cash balance back into the green, says Cowen analyst Phil Nadeau. The analyst believes this resolves a major investor concern. “The key risk facing ACOR investors is the ability of the company to sufficiently fund operations in order to successfully launch Inbrija and achieve cash flow breakeven without meaningful dilution,” the 5-star analyst said. “The sale of ACOR's manufacturing operations, restructuring, and disclosure of strong Q4 Inbrija sales meaningfully increase the likelihood that Acorda's balance sheet is sufficiently strong to support operations back to profitability, in our opinion." In addition to the restructuring, Acorda also offered a glimpse of Q4 financial results.
RBC Capital Stick to Their Buy Rating for Catalent By Investing.com 2021/01/15 01:56:03 Investing.com
RBC Capital Stick to Their Buy Rating for Catalent
Pharmaceutical Contract Manufacturing Market 2030 Key Players Boehringer Ingelheim, Catalent Inc., Famar S.A., Hospira Inc. 2020/12/31 21:31:32 OpenPR
Pharmaceutical Contract Manufacturing Market report provides in-depth statistics and analysis available on the market status of the Pharmaceutical Contract Manufacturing key players and is a valuable method of obtaining guidance and direction for companies and business enterprise insider considering the
Horizon Therapeutics plc Announces Short-Term TEPEZZA® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production 2020/12/17 11:40:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced that it expects a short-term disruption in TEPEZZA (teprotumumab-trbw) supply as a result of recent government-mandated COVID-19 vaccine production orders related to Operation Warp Speed that have dramatically restricted capacity available for the production of TEPEZZA at its drug product contract manufacturer, Catalent. Operation Warp Speed, per its authority provided through the Defense Production Act of 1950, recently
Passage Bio Announces Gene Therapy Manufacturing Research and Development Site 2020/12/16 13:00:00 GlobeNewswire
- Company invests to build in-house capabilities to support advancement of pipeline - - In combination with dedicated CGMP suite at Catalent, the new…
KeyBanc Upgrades Catalent On Industry Transformation 2020/12/10 15:30:14 Benzinga
Catalent Inc (NYSE: CTLT ) is a “key component” of the transformation of the health care industry from pharma to biopharma, according to KeyBanc Capital Markets. The Catalent Analyst: Paul Knight upgraded Catalent from Sector Weight to Overweight with a $120 price target. The Catalent Thesis: An accelerating number of biotech therapies are being approved by the FDA, easily doubling the pace seen in 2000-2010, Knight said in an upgrade note. Amid this trend, contract development and manufacturing organizations “have become of increasing … Full story available on Benzinga.com
Pharmaceutical Contract Manufacturing: Market 2020 Rising Best Technology Trends Research By Major Key Players | Aenova Group, Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent 2020/12/09 12:47:37 OpenPR
Global pharmaceutical contract manufacturing market will reach $184.8 billion by 2030, growing by 6.2% annually over 2020-2030 driven by increasing dependence on contract manufacturing organizations due to improved efficiency and productivity amid COVID-19 pandemic. Pharmaceutical Contract Manufacturing Market 2020 this report
Stock Market Today: Trump's Swing at China Sends Nasdaq Into Correction 2020/09/08 20:46:00 Kiplinger Washington Editors
A stock market that was already full of jitters got something a little more tangible to worry about over the weekend, and that spilled out into Tuesday trade that sent the Nasdaq Composite into a correction. President Donald Trump on Labor Day said America would "end reliance on China once and for all, whether it's decoupling or putting in massive tariffs like I've been doing already." China, meanwhile, announced an initiative to help set global data-security standards -- a counter to America's "Clean Network" guidelines that would exclude some Chinese firms. SEE MORE 20 Best Stocks to Invest In During This Recession Large tech firms took the worst of it, including Tesla ( TSLA , -21.1%). Standard & Poor's surprised many market observers by not adding the electric vehicle maker to the S&P 500 . Instead, online marketplace Etsy ( ETSY ), automatic test equipment supplier Teradyne ( TER ) and health care tech and manufacturing firm Catalent ( CTLT ) will be elevated as of Sept. 21. Out will be tax preparer H&R Block ( HRB ), beauty company Coty ( COTY ) and discount department-store chain Kohl's ( KSS ).
Tesla stock sputters after S&P Dow Jones Indices adds Etsy, Teradyne, and Catalent instead 2020/09/08 16:51:37 Fast Company
Months and months of nonstop growth are coming to an end. After a wild run that saw its share price increase more than fivefold since the start of the year, Tesla continues to spiral back down to earth. Read Full Story
Tesla stock tanks after capital raise, S&P 500 doesn’t add it 2020/09/08 15:36:41 ValueWalk
One thing that has been driving Tesla stock recently is the expectation that it would be added to the S&P 500. However, that didn’t happen, and investors started unloading the shares as a result. The S&P 500 Index Committee added Catalent, Etsy and Teradyne to the index on Friday, but it excluded Tesla stock. Q2 […] The post Tesla stock tanks after capital raise, S&P 500 doesn’t add it appeared first on ValueWalk .
Tesla shares plunge as it fails to make it into S&P 500 index | Business 2020/09/08 14:54:31 Devdiscourse
In a surprise announcement, the S&P Dow Jones Indices decided to add online craft seller Etsy Inc, semiconductor equipment maker Teradyne Inc and pharmaceutical technology company Catalent Inc to the S&P 500 instead. S&P Dow Jones Indices senior index analyst Howard Silverblatt on Friday declined to say why Tesla was not added to the S&P 500.
Tesla shares fall as it fails to make it into S&P 500 index | Business 2020/09/08 12:38:39 Devdiscourse
Wall Street analysts and investors widely expected Tesla to join the S&P 500 after the company posted its fourth consecutive profitable quarter in July, clearing a major hurdle for its potential inclusion in the benchmark stock index. In a surprise announcement, the S&P Dow Jones Indices decided to add online craft seller Etsy Inc, semiconductor equipment maker Teradyne Inc and pharmaceutical technology company Catalent Inc to the S&P 500 instead.
関連キーワード （医薬品 米国株 CTLT キャタレント CTLT ）